Nanocarriers (liposomes, micelles, dendrimers, metallic NPs, quantum dots) enable drug encapsulation, improved solubility, targeted release, and navigating biological barriers—reducing side effects, boosting efficacy.
Cancer therapies target tumors; infectious disease delivery crosses barriers; regenerative medicine uses nanoscale scaffolds; smart implants monitor or deliver drugs; gene therapies use lipid nanoparticles.
Scaling manufacturing, regulatory oversight, nanoparticle toxicity and long-term body/environmental fate are key concerns. Green synthesis and improved clinical trials are essential for safe adoption.
The nanotech drug delivery market is ~$108 billion in 2025, projected to grow ~11.3% annually until 2032. Broader nanomedicine market expected to exceed $655 billion by 2034.